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Neurological Adverse Events to Voriconazole: 
Evidence for Therapeutic Drug Monitoring 
A. Imhof*, D.J. Schaer, M. Schneemann, 
R. Laffer, U. Schanz. Department of Internal 
Medicine University Hospital ZUrich, 8091 ZUrich, 
Switzerland 
Background: Treatment with voriconazoLe (VOR), a 
broad-spectrum second-generation azoLe antifun- 
gaL agent, has been shown to result in favorable 
outcomes in the setting of muLtipLe opportunistic 
fungaL infections. VOR has a considerable interpa- 
tient variation of serum concentrations, and recent 
observations suggest hat adverse vents might be 
close related. 
Objectives: Association of VOR serum Level in- 
crease (sVL) with severe neuroLogicaL adverse 
eve n ts. 
Methods E Results: In a retrospective analysis 
of 28 treatment courses, 6 patients presented 
with neuroLogicaL adverse events (nAE, haLLuci- 
nation, encephaLopathy, and visual disturbance). 
OR per 0.1 pg/mL sVL was 2.34, (95% CI: 1.54-3.55, 
p<0.001). The ROC curve for nAE for each of 
the sVL cut points shows a very good accuracy 
(area under the ROC curve = 0.846). ALL nAE 
occurred within 3 to 22 days (median: 7 days) 
after start of VOR treatment or dosage adjust- 
ment. Longer duration of VOR treatment was sig- 
nificantLy associated with Less nAE (OR per 10 
days of VOR treatment: 0.87, 95%CI: 0.78-0.96, 
p= 0.008). There was no correlation between sVL 
and creatinine (r=0.12, p=0.114), ALT (r=-0.14, 
p = 0.072), AST (r = 0.003, p = 0.964), aLkaLine phos- 
phatase (r=0.03, p=0.723). 
Conclusions: Our findings demonstrate that the 
potential for emergence of neuroLogicaL adverse 
events is associated with elevated sVL and mea- 
surement of serum concentration could improve 
voMconazoLe treatment and safety. 
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Combined Galactomannan (GMn), Mannan (Mn), 
and Anti-Mannan (AMn) for Diagnosis of Invasive 
Fungal Infections (IFI) in Neutropenic Cancer 
Patients (Pts) 
L. Senn*, J.O. Robinson, S. Schmidt, M. Knaup, 
B. Duvoisin, J. BiLLe, T. CaLandra, O. Marchetti. 
Infectious Diseases Service, EHUV, Lausanne, 
Switzerland 
Background: Invasive aspergiLLosis (IA) and can- 
didiasis (IC) are Life-threatening complications in 
neutropenic cancer pts. Diagnosis remains difficult 
and is often delayed when relying on conventional 
methods. Thus, empirical antifungaL Rx is a stan- 
dard of care in neutropenic patients with persistent 
fever. Detection of fungaL antigens and antibodies 
may help to guide antifungaL Rx. 
Objectives: to evaluate the utility of a combined 
monitoring of GMn, Mn and AMn in neutropenic 
cancer patients. 
Methods: Prospective evaluation of consecutive 
episodes of neutropenia (median duration 22 d) in 
pts with acute Leukemia. IFI was diagnosed accord- 
ing to EORTC-MSG criteria. BLood was coLLected 
2 times weekly before onset of fever and daily 
thereafter. GMn, Mn and AMn were measured by 
ELISA (PLateLia, Bio-Rad). Positive tests were de- 
fined by 2 consecutive values of GMn 70.3, 0.4, 0.5 
or >I.0OD Index, of Mn >0.25 or 0.5 ng/mL and of 
AMn >5 or 10AU/mL. 
Results: 14 IA (5 proven, 9 probable) and 13 IC 
(1 proven, 12 probable) occurred in 154 neu- 
tropenic episodes. 16 samples per episode (5-47) 
were analyzed over 35d (17-122). Diagnostic per- 
formance of GMn in IA and Mn/AMn in IC: the 
sensitivity of Lower cut-offs was higher than that 
of the recommended cut-offs, the specificity was 
similar. Diagnostic performance of the combined 
markers: the NPV was high and the LikeLihood ratio 
of a negative test was 0.05. In 87% of Pts with 
IFI, positive tests preceded cLinicaL diagnosis by 
a median of 12d. GM/Mn/AMn became positive in 
the time window during which empirical antifungaL 
therapy is recommended (2.5 d after fever onset). 
Conclusions: In neutropenic cancer patients, se- 
quential monitoring of GMn/Mn/AMn may con- 
tribute, in combination with other diagnostic tests, 
to identify persistently febrile neutropenic patients 
who do not need empirical antifungaL Rx. 
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Beta-l,3-D-Glucan (BGL) Antigenemia in 
Neutropenic Cancer Patients (Pts) with Invasive 
Aspergillosis (IA) and Candidiasis (IC) 
L. Senn*, J.O. Robinson, S. Schmidt, M. Knaup, 
N. Asahi, S. Satomura, S. Matsuura, B. Duvoisin, 
T. CaLandra, O. Marchetti. Infectious Diseases 
Service, CHUV, Lausanne, Switzerland 
Background: IA and IC are associated with high 
morbidity and mortality in neutropenic cancer pts. 
New diagnostic tests are needed for early diagnosis 
of invasive mycosis. BGL, a fungaL ceLL waLL antigen, 
can be detected in the systemic circulation of 
pts with IA or IC. 
